Navigation
Navigation

Capricorn Health-tech Fund

The Capricorn Health-tech Fund (CHF) focuses on human health-technology investments. Health-technologies relate to the prevention, the diagnosis and the treatment of diseases.

iSTAR Medical’s glaucoma device MINIject shows positive one-year results in European trial

News
- 16/11/2020
Growing body of evidence confirms MINIject is safe and effective with results sustained over time. Wavre, Belgium: 16 November 2020 – iSTAR Medical, a medtech company developing minimally invasive ophthalmic implants for treatment of patients…
Read more

Confo Therapeutics announces selection of first product candidate and initiation of pre-clinical development

News
- 15/10/2020
Ghent, Belgium: 15 October 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications.…
Read more

Team
Dr Jos B. Peeters
Chairman of the Executive Committee - Responsible for venture capital, finance and IT
Dr Katya Smirnyagina
Executive Director Capricorn Health-tech Fund

Portfolio

Success stories

Ogeda

Ogeda [Belgium] is a drug development company with a chemistry service business focusing on discovery of small molecules targeting GPCRs.